Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The CD40/CD40L axis in glioma progression and therapy.

Literature DB >> 26206773

The CD40/CD40L axis in glioma progression and therapy.

Paul R Walker¹, Denis Migliorini¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：
CD40 Antigens
CD40 Ligand

Year: 2015 PMID： 26206773 PMCID： PMC4648308 DOI： 10.1093/neuonc/nov138

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

× No keyword cloud information.

13 in total

Review 1. CD40/CD154 interactions at the interface of tolerance and immunity.

Authors: Sergio A Quezada; Lamis Z Jarvinen; Evan F Lind; Randolph J Noelle
Journal: Annu Rev Immunol Date: 2004 Impact factor: 28.527

2. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.

Authors: Masashi Chonan; Ryuta Saito; Takuhiro Shoji; Ichiyo Shibahara; Masayuki Kanamori; Yukihiko Sonoda; Mika Watanabe; Toshiaki Kikuchi; Naoto Ishii; Teiji Tominaga
Journal: Neuro Oncol Date: 2015-05-24 Impact factor: 12.300

3. Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system.

Authors: Jörg Wischhusen; Dagmar Schneider; Michel Mittelbronn; Richard Meyermann; Hartmut Engelmann; Gundram Jung; Heinz Wiendl; Michael Weller
Journal: J Neuroimmunol Date: 2005-05 Impact factor: 3.478

4. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.

Authors: Madiha Derouazi; Wilma Di Berardino-Besson; Elodie Belnoue; Sabine Hoepner; Romy Walther; Mahdia Benkhoucha; Patrick Teta; Yannick Dufour; Céline Yacoub Maroun; Andres M Salazar; Denis Martinvalet; Pierre-Yves Dietrich; Paul R Walker
Journal: Cancer Res Date: 2015-06-26 Impact factor: 12.701

5. CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma.

Authors: Fang Xie; Qin Shi; Qin Wang; Yan Ge; Yongjing Chen; Jianling Zuo; Yongping Gu; Haizhen Deng; Hui Mao; Zhenhua Hu; Yinghui Zhou; Xueguang Zhang
Journal: J Neuroimmunol Date: 2010-03-20 Impact factor: 3.478

6. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Authors: Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
Journal: Science Date: 2011-03-25 Impact factor: 47.728

Review 7. Prospect of targeting the CD40 pathway for cancer therapy.

Authors: Robert H Vonderheide
Journal: Clin Cancer Res Date: 2007-02-15 Impact factor: 12.531

8. CD40 is a prognostic marker in primary cutaneous malignant melanoma.

Authors: J J van den Oord; A Maes; M Stas; J Nuyts; S Battocchio; A Kasran; M Garmyn; I De Wever; C De Wolf-Peeters
Journal: Am J Pathol Date: 1996-12 Impact factor: 4.307

9. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

Authors: Ignacio Melero; Antonio M Grimaldi; Jose L Perez-Gracia; Paolo A Ascierto
Journal: Clin Cancer Res Date: 2013-03-01 Impact factor: 12.531

10. CSF-1R inhibition alters macrophage polarization and blocks glioma progression.

Authors: Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce
Journal: Nat Med Date: 2013-09-22 Impact factor: 53.440

9 in total

The CD40/CD40L axis in glioma progression and therapy.

Review 1. CD40/CD154 interactions at the interface of tolerance and immunity.

2. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.

3. Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system.

4. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.

5. CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma.

6. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Review 7. Prospect of targeting the CD40 pathway for cancer therapy.

8. CD40 is a prognostic marker in primary cutaneous malignant melanoma.

9. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

10. CSF-1R inhibition alters macrophage polarization and blocks glioma progression.

1. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.

2. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).

3. CDCA8 Contributes to the Development and Progression of Thyroid Cancer through Regulating CDK1.

4. CD40L inhibits cell growth of THP-1 cells by suppressing the PI3K/Akt pathway.

Review 5. Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.

6. Soluble CD40 ligand inhibits the growth of non-Hodgkin's lymphoma cells through the JNK signaling pathway.

Review 7. Immunotherapy for glioblastoma: the promise of combination strategies.

Review 8. Manipulating Macrophage/Microglia Polarization to Treat Glioblastoma or Multiple Sclerosis.

Review 9. Tumor-Associated Macrophages in Gliomas-Basic Insights and Treatment Opportunities.